Interferon beta-1a

Interferon beta-1a
Clinical data
Trade names	Avonex, Rebif, Plegridy, others
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a604005
License data	EU EMA: by INN; US DailyMed: Interferon_beta-1a;
Pregnancy; category	AU: D;
Routes of; administration	Subcutaneous, intramuscular
ATC code	L03AB07 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Elimination half-life	10 hrs
Identifiers
	IUPAC name Human interferon beta;
CAS Number	145258-61-3 ;
IUPHAR/BPS	8339;
DrugBank	DB00060 ;
ChemSpider	none;
UNII	XRO4566Q4R;
KEGG	D04554;
ChEMBL	ChEMBL1201562 ;
Chemical and physical data
Formula	C908H1408N246O252S7
Molar mass	20027.14 g·mol−1
	(what is this?) (verify)

Interferon beta-1a (also interferon beta 1-alpha) is a cytokine in the interferon family used to treat multiple sclerosis (MS). It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some research indicates that interferon injections may result in an 18–38% reduction in the rate of MS relapses.

Interferon beta has not been shown to slow the advance of disability. Interferons are not a cure for MS (there is no known cure); the claim is that interferons may slow the progress of the disease if started early and continued for the duration of the disease.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.